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Letter to the EditorAllergen-dependent oxidant forma-
tion requires purinoceptor activation
of ADAM 10 and prothrombinTo the Editor:
Group 1 allergens, exemplified by Der p 1, are the most
significant triggers within the allergenic repertoire of house dust
mite (HDM) proteins capable of eliciting the intracellular gener-
ation of reactive oxidant species (ROS) by airway epithelial
cells.1 This is because Der p 1, a cysteine peptidase, behaves as a
prothrombinase, thereby triggering canonical activation of
protease-activated receptor (PAR) 1 and 4 by thrombin.1 These
events are preventable by Allergen Delivery Inhibitors or antago-
nists of PAR1 and PAR4 G-protein–coupled receptors.1 Intracel-
lular ROS formation by any allergen is noteworthy because
asthma is associated with deficits in antioxidant defences1 and
ROS promote inflammation through transcription factor regula-
tion, histone modifications, and the direct activation of signal
transduction. The partially delineated pathway that leads to
ROS production by HDM allergens converges with signaling
from the ligation of Toll-like receptor 3 or melanoma differentia-
tion–associated protein-5, which are key in host responses to res-
piratory viruses associated with asthma exacerbations.1 This
convergence opens pannexons, releasing ATP, which is essential
for allergen and viral RNA-dependent ROS production.1 Other
pertinent effects of ATP include stimulation of IL-33 release,
TH2 bias in dendritic antigen presenting cells, mast cell activa-
tion, and dyspnea.
‘‘Sheddase’’-dependent activation of epidermal growth factor
receptor is implicated in G-protein–coupled receptor crosstalk, so
we explored whether HDM allergen-dependent ROS generation
requires the participation of sheddase metalloenzymes, especially
those of the a disintegrin and metalloprotease (ADAM) family.
To investigate the production of intracellular ROS, we loaded
human airway epithelial cells with dihydrorhodamine 123 and
exposed them to a natural mixture of Dermatophagoides ptero-
nyssinus allergens or 29(39)-O-(4-benzoylbenzoyl)adenosine 59-
triphosphate (BzATP) and uridine 59-triphosphate (UTP) (to
mimic the activation of P2X7 and P2Y purinoceptors by
endogenously-released ATP) (see the Methods section in this ar-
ticle’s Online Repository at www.jacionline.org).
Exploration ofmetalloenzymes capable of ectodomain cleavage
or regulated intracellular proteolysis was prompted by the finding
that epidermal growth factor receptor signaling is crucial for ROS
generation in cells stimulated by HDM allergens, BzATP or UTP
(see Fig E1, A-C, in this article’s Online Repository at www.
jacionline.org). The metalloenzyme inhibitors marimastat and
TAPI-1 (N-[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-
oxopentyl]-3-(2-napthalenyl)-1-alanyl-N-(2-aminoethyl)-1-alani-
namide acetate) blunted ROS production by either HDM allergens
or BzATP (see Fig E2, A-D, in this article’s Online Repository at
www.jacionline.org). Surprisingly, TAPI-2 (N-(R)-(2-(hydroxya-
minocarbonyl)methyl)-4-methylpentanoyl-L-t-butyl-glycine-L-
alanine 2-aminoethyl amide acetate) (which has greater 2017 The Authors. Published by Elsevier, Inc. on behalf of the American Academy of
Allergy,Asthma& Immunology. This is an open access article under theCCBY license
(http://creativecommons.org/licenses/by/4.0/).selectivity than TAPI-1 for the ‘‘classical’’ sheddase ADAM
17) did not affect responses to BzATP, although it was an effec-
tive inhibitor of mixed HDM allergens (see Fig E2, E and F).
From these results, and consistent with additional data (see Fig
E3, A-D, in this article’s Online Repository at www.jacionline.
org), we inferred that ROS production involved a metallopro-
tease component distinct from ADAM 17.
Unexpectedly, the potent and selective ADAM 10 inhibitor, GI
254023X, attenuated intracellular generation of ROS by HDM,
and was particularly efficacious in cells stimulated by BzATP or
UTP (Fig 1, A-C), whereas it lacked effect in quiescent cells. Sub-
stantial involvement of ADAM10 in responses to all 3 stimuli was
confirmed by siRNA knockdown (Fig 1, D-F). As further proof,
exogenously added recombinant human ADAM 10 elicited
concentration-dependent ROS generation, which was inhibited
by GI 254023X, thus authenticating its action (Fig 2, A-C). The
effect of ADAM10was sensitive to AG 1478, confirming a recep-
tor tyrosine-kinase–dependent component of the activation cycle
(Fig 2, D).
Surprisingly, argatroban inhibited responses to rhADAM 10,
implying the formation of thrombin (Fig 2, E). We have previ-
ously shown that Der p 1 is a prothrombinase,1 confirmed here
by demonstrating that siRNA knockdown of prothrombin attenu-
ated the response to mixed HDM allergens (see Fig E4, A, in this
article’s Online Repository at www.jacionline.org). Moreover, we
have now found that prothrombin knockdown blunted the re-
sponses to BzATP or UTP (Fig 2, F and G). This is consistent
with ADAM 10 activation, which we show to be downstream
from purinoceptor stimulation, operating a pathway to enhance
thrombin formation. The principle of metalloprotease-initiated
thrombin formation and ROS production was further exemplified
using the snake venom protease, ecarin, whose ability to activate
prothrombin by proteolytic cleavage is well established from its
use as a clinical diagnostic in the ecarin clotting test. Like
ADAM 10, ecarin is a member of the M12B protease subfamily
and comprises metalloprotease, disintegrin, and cysteine-rich do-
mains. Like ADAM 10, ecarin is a potent generator of intracel-
lular ROS (Fig E4, B). Detailed biochemical studies
investigating the activation of prothrombin by ADAM 10 are un-
derway and will be reported separately.
Our data implicate purinoceptor-dependent activation of
ADAM 10 as a downstream effector of ROS production in an
innate response to HDM allergens. Significantly, ADAM 10
establishes a signaling cycle capable of sustaining prothrombin
activation after its initiation by group 1 HDM allergens.1 In addi-
tion, as the principal sheddase of the adherens junction protein, E-
cadherin,2 activation of ADAM 10 has the potential to augment
any dysregulation of the epithelial barrier arising from targeted
cleavage of tight junctions by group 1 HDM allergens.3
These findings expand the growing pleiotropic role ofADAM10
in allergy. Illustratively, ADAM 10 drives TH2 bias
4 and promotes
IgE synthesis by being a CD23 sheddase,5 an effect incidentally
ascribed to Der p 1 itself.3 In airway epithelial cells, ADAM10 lib-
erates CCL20 (which recruits dendritic cells and TH17 cells and
promotes mucus hyperplasia), CCL2 (chemoattractant for den-
dritic cells), CCL5 (eosinophil chemokine), CXCL8 (neutrophil
chemokine), and CXCL16 (T-cell chemoattractant).6,7 It is also
involved in stem cell factor-dependent mast cell migration.1
FIG 1. Inhibition by GI 254023X suggests that ADAM 10 is a mediator of intracellular ROS production by (A)
HDM allergens (*P < .001 vs vehicle [veh], P < .05-0.001 vs HDM 1), (B) BzATP (*P < .001 vs veh, P < .001 vs
BzATP, **P < .05 vs veh), (C) UTP (*P < .001 vs veh, P < .001 vs UTP). D-F, ADAM 10 gene silencing also
reduces these responses (*P < .001 vs veh, P < .001 vs HDM 1, BzATP, or UTP with or without control trans-
fection, P < .05 vs BzATP). RFU, Relative fluorescence units.
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FIG 2. Recombinant human (rh) ADAM 10 stimulates intracellular ROS formation in airway epithelial cells.A
and B, Progress curves and concentration-response relationship for dihydrorhodamine oxidation following
vehicle (veh) or rhADAM 10. All concentrations P < .001 with respect to the dashed line. C-E, Inhibition by GI
254023X, AG 1478, or argatroban, respectively, of responses to ADAM 10. BzATP is shown for reference
(*P < .001 vs veh, **P < .001 vs ADAM 10, P < .01 vs veh, P < .001 vs veh). F, Gene-silencing prothrombin
(PT) blunts the response to BzATP (*P < .001 vs veh, **P < .05 vs BzATP, P < .05 vs BzATP stimulation in
control transfection, P < .001 vs BzATP stimulation). G, As in Fig 2, F, but stimulation by UTP (*P < .001 vs
veh, **P < .001 vs UTP, P < .05 vs UTP stimulation in control transfection, P < .001 vs UTP). RFU, Relative
fluorescence units; rhADAM 10, recombinant human ADAM 10.
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4 LETTER TO THE EDITORADAM10 expression is upregulated in amodel of asthma and onB
cells in patients with allergy and in TH2-prone mice.
8,9 The combi-
nation of high ADAM 10 expression on B cells within a TH2 cyto-
kine environment causes mimicry of disease pathophysiology,
namely,mucus cell hyperplasia, airway constriction, inflammation,
and IgE production, whereas development of these is attenuated in
mice deficient in ADAM 10.9
Intriguingly, ADAM 10 is also the cellular receptor for Staph-
ylococcus aureus a-hemolysin toxin,2 suggesting that ADAM
10–dependent responses to allergens and infections, both viral
and bacterial, may represent a signaling nexus in chronic severe
disease exacerbations, which merits further examination in the
clinic.
Additional information is available (see this article’s Methods,
Results, and References section in the Online Repository at www.
jacionline.org).
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Group 1 allergens from HDMs form a novel subfamily of C1
cysteine peptidases differentiated by structural and functional
differences in their zymogen prodomains.E1,E2 Persuasive evi-
dence indicates that the proteolytic activity of these HDM al-
lergens activates a mixture of physical events and innate
immune responses that promote the development of persistent
allergic sensitization to any allergen.E2,E3 This occurs because
the proteolytic bioactivity nonselectively increases the proba-
bility of contact with dendritic antigen presenting cells and fa-
cilitates the polarization to allergic immunity through a
combination of mechanisms: recapitulation of these processes
maintains sensitization and promotes pathophysiological
changes.E2
Group I allergens from all species of HDM have a highly
conserved sequence identity such that they could be considered
as a single drug target in the design of first-generation Allergen
Delivery Inhibitor drugs directed against their cysteine protease
activity.E4 Der p 1 from D pteronyssinus, commonly used as the
general exemplar of these allergens, has recently been identified
as the dominant component in the allergenic repertoire of HDM
that stimulates the formation of superoxide anion (O2
2) in mito-
chondria of human airway epithelial cells.E5 The production of
this ROS is independent of IgE. Rather, it is part of a signaling
cascade initiated by the conversion of prothrombin to thrombin
by Der p 1, the consequent activation of PAR 1 and PAR 4 and
the G-protein–coupled receptor signal transduction pathways
coupled to them, the extracellular release of ATP, and the stim-
ulation of purinergic signaling inter alia through P2X7
receptors.E5
In the airways, peptidase allergen to ROS signaling may be
relevant to the pathogenesis of asthma because ROS exert a TH2
bias to immune responses. This riskmay be exacerbated by deficits
in enzymatic and/or nonenzymatic antioxidant defences.E6-E10
Furthermore, components of the signaling mechanism activated
by Der p 1 (eg, ATP and thrombin) are themselves implicated as
primary transducers of innate immunity, which predispose to the
development of acquired TH2 responses,
E5,E11-E13 and/or they un-
derlie fundamental aspects of asthma pathophysiology.E14-E17
Illustratively, thrombin—which is present in asthmatic airways
in elevated amountsE18,E19—is mitogenic in airways smooth mus-
cle, is profibrogenic, and fosters the TH2 polarization of responses
in dendritic antigen presenting cells.E14,E18 Also present in asth-
matic airways at elevated concentration is ATP,E12 which has
wide-ranging effects beyond the capacity to evoke neurogenic
bronchoconstriction and dyspnea.E20 For example, ATP stimulates
the release of IL-33 from airway epithelial cells,E13 augments IgE-
dependent mediator release frommast cells,E21 and is another fac-
tor known to activate dendritic antigen presenting cells with a TH2
bias.E12 Moreover, intracellular ROS themselves have established
roles in upregulating the expression of proinflammatory genes
through operation of redox-sensitive transcription factors such as
nuclear factor kappa B, AP-1, and Sp1,E22 histone modification
and activation of signaling via members of the mitogen-
activated protein kinase, and signal transducers and activators of
transcription families.E6
In the experiments described here, we investigated the role of
endogenous epithelial proteases in the signal transduction
pathway leading to ROS production by Der p 1. Our specific
focus was the role of zinc metalloproteases, especially ADAM
enzymes. This supplementary information provides background





N-hydroxyacetamide), CL 82198 (N-[4-(4-morpholinyl)butyl]-2-benzo-
furancarboxamide hydrochloride), GI 254023X ((2R)-N-[(1S)-2,2-dimethyl-
1-[(methylamino)carbonyl]propyl]-2-[(1S)-1-(N-hydroxyformamido)ethyl]-
5-phenylpentanamide), WAY 170523 (N-[2-[4-[[[2-[(hydroxyamino)
carbonyl]-4,6-dimethylphenyl](phenylmethyl)amino]sulfonyl]phenoxy]
ethyl]-2-benzofurancarboxamide), and AG1478 (N-(3-chlorophenyl)-6,7-
dimethoxy-4-quinazolinanine hydrochloride) were obtained from Tocris
(Avonmouth, Bristol, United Kingdom [UK]).
TAPI-1 acetate (N-[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-
oxopentyl]-3-(2-naphthalenyl)-l-alanyl-N-(2-aminoethyl)-l-alaninamide ace-




methyl-2-piperidinecarboxylic acid), marimastat ((2S,3R)-N4-[(1S)-
2,2-dimethyl-1-[(methylamino)carbonyl]propyl]-N1,2-dihydroxy-3-(2-
methyl-propyl)butanediamide), BzATP (29(39)-O-(4-benzoylbenzoyl)
adenosine 59-triphosphate triethylammonium salt), UTP (uridine 59-
triphosphate trisodium salt dehydrate), LPSs from Escherichia coli
0111:B4, and human thrombin were from Sigma-Aldrich (Poole,
Dorset, UK). Dihydrorhodamine-123 was obtained from Life Technolo-
gies (Paisley, Renfrewshire, UK).
Cell culture media and reagents were obtained from Life Technologies,
Sigma-Aldrich, and GE Healthcare (Little Chalfont, Buckinghamshire, UK).
Transfection reagents and siRNA duplexes (typically mixtures of 3 target-
specific 19-25 nt siRNAs or scrambled controls against no known targets)
were obtained from Santa Cruz Biotechnology (Dallas, Tex). Baculovirus-
derived, rhADAM 10 (Thr214 – Glu672) expressed in sf21 cells was obtained
from R&D Systems (Abingdon, Oxfordshire, UK). Ecarin from Echis carina-
tus venom and thrombin from human plasmawere supplied by Sigma-Aldrich.
Mixed, native HDM allergens in their natural proportions were prepared
from laboratory cultures ofD pteronyssinus according to our standard proced-
ures. Der p 1 content of the allergen extracts was determined by ELISA (In-
door Biotechnologies, Cardiff, UK), whereas functional catalytic activity of
Der p 1 was determined fluorimetrically using a Der p 1–selective substrate
as described elsewhere.E4,E5 HDM mixtures were normalized by reference
to Der p 1 content expressed as mg/mL. Thus, HDM 1 refers to mixed
HDMwhose Der p 1 concentration is 1 mg/mL. Normalization was necessary
because the extracts contain multiple components and batch-to-batch varia-
tion in activity is seen. Der p 1 is the most important normalization denomina-
tor in these studies because it is the principal active component responsible for
intracellular ROS generation.E4 For consistent batch-to-batch proteolytic ac-
tivity of Der p 1 in allergen preparations, experiments were conducted in
the presence of 5 mM L-cysteine. Endotoxin content in allergen preparations
was determined by kinetic chromogenic limulus amebocyte assay (Endo-
chrome-K, Charles River Laboratories International, Inc, Wilmington,
Mass) according to manufacturer instructions.
Cell culture and transfection
Calu-3 cells, which are both well validated and a relevant cellular model for
these investigations, were cultured according to our standard procedures as
described elsewhere.E23-E25 Our previous work has demonstrated that ROS
generation by HDM allergen treatment of calu-3 cells is mechanistically
similar to responses seen in primary cultures of human airway epithelium.E5
Knockdown experiments with siRNA duplexes were performed according
to the supplier protocol optimized for these experiments.
Intracellular ROS production was studied in cells plated into 96-well
format on clear-bottomed black culture plates (Corning, Amsterdam,
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The Netherlands). Cells were washed and then loaded for 15 minutes at room
temperature with dihydrorhodamine-123 (10 mM) in PBS, after which excess
probe was removed by washing and the PBS replaced by HBSS containing
20 mMHEPES. Where appropriate, cells were then treated with inhibitors for
20 minutes at 378C before the addition of HDM allergen or receptor agonists.
Reactions were started by the addition of an appropriate stimulant (mixed
HDM allergens, purified Der p 1, rhADAM 10, or LPS) and maintained at
308C under constant humidity in an Envision plate reader (Perkin Elmer, Seer
Green, Buckinghamshire, UK) for the duration of the experiment. Fluores-
cence measurements were made every 5 minutes (excitation 485 nm, emission
535 nm), and the maximum rate of oxidant production determined from the
progress curves (increase in fluorescence upon oxidation of
dihydrorhodamine-123 to rhodamine) recorded for each well over a 2.5-
hour period.
Statistical analyses
Analyses were performed using SigmaPlot v12. Data are shown as
mean 6 SEM (n 5 8) in single experiments, which were replicated more
than 3 times. Significance was determined using 1-way ANOVA with
Newman-Keuls post hoc testing.
RESULTS
Modulation of intracellular oxidant formation by
inhibition of metalloproteases and thrombin
formation
To investigate the IgE-independent production of ROS by
allergen exposure, cells were treated with a natural mixture
containing all HDM allergens. To elucidate the role of ATP in
signaling, we used BzATP and UTP to achieve stimulation of
P2X7 and P2Y receptors, respectively. Responses to HDM and
BzATP were inhibited by AG1478, which indicated a role for
epidermal growth factor receptor (EGFR) signaling (Fig E1, A).
This was confirmed by siRNA knockdown in cells stimulated
with mixed HDM allergens, BzATP or UTP (Fig E1, B and C).
Given that their involvement in the generation of EGFR agonists
or other sheddable ligands is established, this led us to investigate
the role of matrix metalloproteases (MMPs) and ADAMs in the
signal transduction pathway(s) operated by HDM allergen
stimulation.
Both marimastat and TAPI-1 were concentration-dependent
inhibitors of ROS generation in airway epithelial cells stimulated
by mixed HDM allergens or BzATP (Fig E2, A-D). In contrast,
while being an effective inhibitor of HDM-evoked ROS forma-
tion (Fig E2, E), TAPI-2 was inactive when BzATP was the stim-
ulant (Fig E2, F). These results suggested an involvement of
multiple metalloproteases in ROS generation in airway epithelial
cells, so studies were conducted to explore possible candidates.
Conventionally regarded as an inhibitor of MMP-13, MMP-
9, ADAM 17, and, less effectively, MMP-1, compound WAY
170523 inhibited intracellular ROS production by both mixed
HDM allergens and BzATP, whereas the selective MMP-13
inhibitor CL 82198 was ineffective (Fig E3, A-C). The effects
of WAY 170523 showed complexity, however, in affecting
baseline ROS production. At low concentrations of WAY
170523 this was stimulated, whereas the highest concentration
suppressed ROS production below baseline (Fig E3, B). Hu-
man airway epithelial cells are sources of other metallopro-
teases, notably MMP-2, which is a target of marimastat, a
broad-spectrum hydroxamate inhibitor. However, ARP 100,
which has greater selectivity, did not attenuate responses in
cells activated by mixed HDM allergens, thus excluding a
significant role for MMP-2 in this pathway of intracellular
ROS formation (Fig E3, D).
Confirming the essential role of thrombin formation in this
pathway of ROS formation suggested by our previous work,E5 re-
sponses to HDM allergens were strongly attenuated in cells
treated with siRNA duplexes targeting prothrombin (Fig E4, A).
Additional studies revealed that treatment of cells with ecarin, a
snake venom metalloprotease related to ADAM 10 and a known
activator of prothrombin, was also a stimulus for ROS production,
consistent with the principle that ADAM10 (or its targets) may be
a hitherto unrecognized endogenous activator of prothrombin
(Fig E4, B). Although CL 82198 lacked effect against activation
by mixed HDM allergens (Fig E3, C), it was an inhibitor of
ROS production by exogenous thrombin (Fig E4, C). GI
254023X was a potent inhibitor of responses to exogenous
thrombin (Fig E4, D), as anticipated from an involvement of
ADAM 10 in the signaling pathway connecting thrombin gener-
ation by HDM to ROS production.
In contrast to stimulation by mixed HDM allergens, bacterial
LPS was a weak activator of intracellular ROS production, with
significant stimulation observed only at concentrations of more
than 1000 endotoxin unit/mL (Fig E5).
DISCUSSION
In the associated Letter to the Editor and this accompanying
supporting information, we provide the first evidence implicating
ADAM 10 as a crucial component of innate immune responses
that trigger the intracellular formation of ROS when airway
epithelial cells are stimulated byHDMallergens fromDpteronys-
sinus. As demonstrated in our previous work, this effect is due to
the proteolytic activity of Der p 1 because it can be replicated by
the purified allergen and blocked by potent, selective inhibitors
specifically designed to target the proteolytic bioactivity of this
allergen.E5 Bacterial LPSs, inevitably present in allergen mix-
tures derived from natural cultures and occurring as contaminants
in purified allergens derived therefrom, are potent activators of
ROS formation in numerous cell types. As further demonstration
that HDM-induced generation of intracellular ROS in human
airway epithelial cells is primarily dependent on the proteolytic
bioactivity of Der p 1, we now show evidence that unambiguously
demonstrates that LPS, when present at levels found in our
allergen preparations, fails to evoke significant intracellular
ROS activation.
The involvement of ADAM 10 in the pathway of HDM
allergen-dependent intracellular ROS generation adds a further
dimension to the emerging appreciation of this enzyme’s role in
the initiation and maintenance of allergy. In addition to these,
another well-established target of ADAM10, and also ADAM17,
is HB-EGF—notable for its roles in re-epithelialization and the
regulation of mitogenesis in smooth muscle and fibroblasts.E26
Generation of intracellular ROS in airway epithelial cells by
mixed HDM allergens requires the cysteine peptidase activity of
group 1 allergens. These allergens are the binding targets of ADZ
51,457 and ADZ 51,529, compounds that are effective inhibitors
of ROS formation and that exhibit anti-inflammatory activity
in vivo.E4,E5 Previous work identified the initiating step in ROS
production as the activating cleavage of prothrombin to thrombin
by Der p 1.E5 Der p 1, and by reasonable inference all other group
1 mite allergens, can thus be regarded in this context as a pro-
thrombinase. Thrombin then stimulates PAR1 and PAR4 to
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launch a cascade of signaling events, including ATP release,
which culminate in the formation of ROS in mitochondria and
nuclei.E5
Given that the generation of intracellular ROS by BzATP and
UTPwas also dependent onADAM10, it is reasonable to conclude
that a significant role in ROS generation by this sheddase occurs
downstream of pannexon channel opening and ATP release. This
inference is supported by pharmacologic datawithmetalloprotease
inhibitors. Although TAPI-2, a potent inhibitor with good selec-
tivity for ADAM 17, attenuated ROS production by HDM allergen
treatment, it was ineffective against BzATP. Moreover, metal-
loenzyme inhibitors (marimastat, TAPI-1, WAY 170523), which
have less selectivity for ADAM 17, were surprisingly effective
inhibitors of responses to both BzATP and HDM allergens.
The unexpected contribution of ADAM10 to intracellular ROS
formation was revealed by demonstrating that pharmacological
inhibition or knockdown of ADAM 10 reduced the responses to
HDM allergens, BzATP and UTP. Exogenously added ADAM 10
elicited sustained ROS generation, which was inhibited by
blockade of EGFR tyrosine kinase signaling. The ability of
EGFR signaling inhibition or EGFR knockdown to strongly
attenuate ROS generation by HDM allergens, BzATP and UTP,
together with evidence that both ADAM 10 and ADAM 17
contribute to ROS generation suggests that the mechanism
involved is the hub of an innate signaling network comprising
several pleiotropic elements.
Our data suggest thatADAM17 activation and at least 1 instance
of EGFR signaling probably lie upstream from the opening of
pannexon channels, whereas ADAM 10 and further EGFR
signaling lie downstream. Receptor crosstalk between EGFR and
G-protein—coupled receptors is well documented and, specif-
ically, a precedent for PAR-EGFR cross-talk exists.E27 Thus, given
our earlier findings,E5 ADAM 17/EGFR-dependent events may be
closely coupled to the thrombin-mediated activation of PAR 1 and
PAR 4 by Der p 1, through intramembrane events and/or an in-
crease in intracellular calcium arising from PAR activation. In
the case of ADAM 10, whose ligand shedding activity is also cal-
cium dependent,E28,E29 the calcium signal may partly depend on
the opening of the P2X7 channel and protein kinase C activation af-
ter the binding of ATP by P2X7 and P2Y receptors, respectively.
Extracellular ATP is present at elevated levels in the airways in
asthma and is a bronchoconstrictor that produces profound dysp-
nea.E20 It exacerbates IgE-mediated release of histamine, stimu-
lates mediator release by eosinophils, and polarizes dendritic
cells into TH2-directed responses.
E11,E12,E21 The ability of Der p
1 to cause ATP release through an innate mechanism that exists
alongside IgE-mediated responses suggests that investigation of
the chronic corollaries of these innate effects may reveal new in-
sights into the initiation of disease pathophysiology. The present
studies delineate novel mechanisms whose further understanding
will require appropriate preclinical and clinical in vivo models.
An anomaly noted during the pharmacological studies con-
cerned the selective MMP-13 inhibitor, CL 82198. This was
without effect on ROS production elicited by HDM allergen
treatment, yet it was a potent inhibitor when responses were
evoked directly by exogenous thrombin. Thrombin promotes
MMP-13 expression,E30 which itself is a noncanonical activator
of PAR 1 and an epithelial sheddase,E31,E32 so the differential
sensitivity may therefore simply reflect mass action disparities.
However, a reasonable inference from these experiments is that
MMP-13 is another putative regulator of ROS production.
In summary, this study provides the first evidence for ADAM
10 proteolytic activity as an essential molecular component in the
critical path that couples the innate detection of Der p 1 with the
generation of intracellular and extracellular signals that have the
capacity to initiate, develop, and maintain a predisposition to the
immunological profile and pathophysiology of asthma. These
findings invite the further clinical examination of these events,
especially in the context of poor antioxidant status.
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FIG E1. Generation of ROS by HDM allergens in airway epithelial cells is dependent on EGFR receptor
tyrosine kinase signaling. A, Concentration-dependent inhibition by AG1478 of ROS production by HDM al-
lergens (triangles) or BzATP (circles) (P < .001 vs control HDM, P < .001 vs control BzATP). B, EGFR-
directed siRNA reduces the response to HDM allergens (*P < .001 vs vehicle [veh], P < .001 vs HDM aller-
gens in cells with or without control [con] transfection). C, Reduction in ROS generation activated by BzATP
or UTP in cells treated with EGFR-directed siRNA (*P < .001 vs veh, P < .001 vs BzATP or UTP with or
without con transfection). RFU, Relative fluorescence units.
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FIG E2. Effects of metalloprotease inhibitors on ROS generation in human airway epithelial cells stimulated
by either HDM allergens or BzATP. A,Marimastat has no effect on baseline ROS production (left panel) but
inhibits the response to HDM allergens (right panel) (*P < .001 vs vehicle [veh] or marimastat control,
P < .001 vs cells activated with HDM in the absence of marimastat). B, Concentration-dependent inhibition
of HDM responses by TAPI-1 (*P < .001 vs veh, P< .05, P < .001 vs HDM 1). C, Inhibition of BzATP by TAPI-1
(*P < .001 vs veh, P < .001 vs BzATP). D, Inhibition of BzATP by marimastat (*P < .001 vs veh or marimastat
in unstimulated cells, P < .001 vs BzATP control). E, Inhibition of the response to HDM allergens by TAPI-2.
The control response to HDM allergens is displayed in the left section as a bar graphwithmean6SE shown,
and as a dotted line in the concentration-inhibition curve in the right section of this panel (*P < .001 vs veh or
TAPI-2 control, P < .001 vs HDM 1). F, Lack of effect of TAPI-2 on the response to BzATP (*P < .001 vs veh or
TAPI-2 control). RFU, Relative fluorescence units.
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FIG E3. Effects of metalloprotease inhibitors on ROS generation activated by HDM allergens. A,Modulation
of baseline ROS production in airway epithelial cells byWAY 170523 (*P < .001, **P< .01 vs vehicle [veh]). B,
Inhibition of HDM allergen- or BzATP-dependent ROS production by WAY 170523 (*P < .001 vs veh,
**P < .05-.001 vs HDM, P < .001 vs BzATP). C, Effect of CL 82198 on baseline ROS production and lack
of action against HDM allergens (*P < .001 vs veh, **P < .05 vs veh, P < .001 vs veh). D, Effect of ARP
100 on baseline ROS production and failure to inhibit the response to HDM allergens (*P < .001 vs veh,
P 5 .01 and P < .001 vs HDM allergen). RFU, Relative fluorescence units.
J ALLERGY CLIN IMMUNOL
VOLUME nnn, NUMBER nn
LETTER TO THE EDITOR 4.e7
FIG E4. Thrombin dependency of intracellular ROS generation in airway epithelial cells. A, Knockdown of
prothrombin (PT) expression by siRNA blunts the response to stimulation by mixed HDM allergens
(*P < .001 vs vehicle [veh], P < .05 vs HDM stimulation in cells with control [con] transfection, P < .001
vs HDM stimulation). B, Concentration-dependent generation of ROS by the snake venom protease, ecarin.
Dashed line shows ROS production rate in unstimulated cells. C, CL 82198 inhibits ROS generation by exog-
enous thrombin (*P < .001 vs veh, P < .001 vs thrombin, P < .05 vs veh). D, GI 254023X inhibits ROS gen-
eration by exogenous thrombin (*P < .001 vs veh, P < .001 vs thrombin). RFU, Relative fluorescence units.
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FIG E5. LPS fails to emulate intracellular ROS production by mixed HDM
allergens in airway epithelial cells. (*P < .001 vs vehicle [veh], P < .05 vs
veh). LPS content of the mixed HDM preparation was 2.75 endotoxin unit/
mL under the conditions of these experiments. RFU, Relative fluorescence
units.
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